Background. We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II-III breast cancer to evaluate correlations with primary tumor biology. Methods. CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescenceactivated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNAseq and NanoString PAM50 assays with risk of recurrence (ROR) scores. Results. CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. Conclusion. It is feasible to use RNA-seq of CTCs in nonmetastatic patients to discover novel tumor biology characteristics.
CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. Conclusion. It is feasible to use RNA-seq of CTCs in nonmetastatic patients to discover novel tumor biology characteristics.
Circulating tumor cells (CTCs) are malignant cells that have shed into the bloodstream from primary or metastatic cancer tissue and are implicated in cancer metastasis. 1 The presence of CTCs in both metastatic and non-metastatic breast cancer patients has been shown to be associated with poorer survival. [2] [3] [4] In non-metastatic populations, detection of even a single CTC was correlated with poorer clinical outcomes and occurred in fewer than 25% of patients. [3] [4] [5] Some evidence suggests that CTC enumeration may allow detection of disease progression earlier than imaging studies. 6, 7 Although CTC enumeration assays are prognostic, they are not predictive of what type of therapy a breast cancer patient requires.
To fully realize the potential of CTCs as a useful liquid biopsy biomarker, detailed molecular profiling of CTCs must inform the discovery of therapeutic predictors and druggable targets. Our group focused on gene expression profiling (RNA-seq) of CTCs since not all DNA mutations are expressed, and detailed examination at the RNA level allows for determination of the signaling pathways that are potentially targetable. Few studies have characterized the whole transcriptome phenotype of either single or small pools of CTCs in stage IV breast cancer, [8] [9] [10] [11] and, to our knowledge, none have reported this in non-metastatic breast cancer.
We have previously reported that EpCAM-based immunomagnetic enrichment followed by fluorescenceactivated cell sorting (IE/FACS) in combination with whole transcriptome gene expression profiling at the single cell or picogram input level is feasible for rare CTCs, with high accuracy. 8, [12] [13] [14] In this study, we conducted a prospective, observational study to determine the feasibility of EpCAM-based IE/FACS CTC capture followed by RNA-seq for the evaluation of known and novel biomarkers to predict treatment response.
METHODS

Study Subjects
Eligibility was limited to female patients with biopsyproven stage II-III breast cancer without prior therapy. The study was approved by the Institutional Review Board of the University of Southern California (USC), and was compliant with the REMARK criteria. 15 
Blood Draws and Tumor Tissue Acquisition
All de-identified, annotated samples were collected at baseline (prior to therapy). Twenty milliliters of peripheral blood (PB) was drawn into EDTA tubes. An aliquot of 200 lL of PB was placed in 600 lL of RNAlater (Thermo Fisher Scientific, Carlsbad, CA, USA) and stored at -80°C until further use.
Clinical pathology reports utilized the 2010 American Society of Clinical Oncology and College of American Pathologists breast cancer biomarker guidelines. 16 Formalin-fixed, paraffin-embedded (FFPE) primary tumors (PTs) were requested from the Pathology Department for each patient. A total of five 10 lM sections each were used for RNA extraction using the RNeasy FFPE kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. RNA was eluted in 15 lL of RNase-free water.
Circulating Tumor Cell (CTC) Isolation (Immunomagnetic Enrichment Followed by Fluorescence-Activated Cell Sorting)
CTCs were isolated and captured as previously reported using a rapid processing method yielding highly purified CTCs within 3 h of blood draw (assays began within 20 min of blood draw). 8, 12 Briefly, our IE/FACS assay involved immunomagnetic separation using EpCAM (MJ37) monoclonal antibody (mAb)-coated magnetic beads followed by FACS with PE mouse anti-human EpCAM (EBA-1), Thioflavin T buffer dye, and PerCPCy5.5 mouse anti-human CD45 (2D1) for exclusion of leukocytes (BD Biosciences, San Jose, CA, USA) [electronic supplementary Table 1 ]. Analysis of each CTC specimen included BT474 as internal positive and negative gating controls, as well as fluorescence compensation controls using BD CompBeads. CTCs were sorted into 5 lL Prelude Direct Lysis Module (NuGEN, San Carlos, CA, USA). A threshold of a single cell meeting these criteria was qualified as a positive test result. All lysates were immediately stored at -80°C.
RNA-Seq Library Preparation and Sequencing
For sequencing library preparation from all sorted CTC samples, duplicate aliquots of 1 lL cell lysate were used as direct input for sequencing library preparation using the Ovation Single Cell RNA-Seq System (NuGEN). For PB, total RNA isolation was performed using the QIAamp RNA Blood Mini Kit (QIAGEN). RNA-seq library preparation for PB and PTs was performed using the NuGEN Ovation RNA System V2 and NuGEN Ultra Low Library System V2. The quality and quantity of amplified libraries were evaluated using Qubit (Invitrogen, Carlsbad, CA, USA) and Agilent Bioanalyzer 2100 analysis (Agilent Technologies, Santa Clara, CA, USA).
All libraries were sequenced using an Illumina HiSeq 2500 at the University of California, Los Angeles, Clinical Microarray Core with 100 bp paired end reads. FASTQ files were stored on the High Performance Computer Cluster of USC.
NanoString PAM50
NanoString nCounter gene expression assays using the PAM50 CodeSet (research use only) were performed as per the manufacturer's specifications (NanoString Technologies, Seattle, WA, USA). 17, 18 Breast cancer molecular subtype classification was predicted using the genefu package in R for both the NanoString and RNA-seq assays. 19 Bioinformatics Analysis of the RNA-Seq Data Initial read quality and adaptor content of FASTQ files was assessed using FastQC. 20 Reads were then trimmed based on quality score, and adaptor sequences removed using Trimmomatic. 21 After filtering, surviving reads were checked again in FastQC to ensure that only high-quality transcriptome reads were put into the analysis pipeline. These high-quality reads were mapped to the human genome (ver. GRCh38.p7) using the ultra-fast aligner STAR; 22 the same software was used to obtain uniquely mapping read counts for each gene feature included in a Gene Transfer Format (GTF) file. Both the genome and the GTF file were downloaded from the GENCODE database (https://www.gencodegenes.org). Samples with a very low number of uniquely mapping reads (\ 300,000) were omitted from any downstream analysis.
No background subtraction was performed for the CTC samples as our CTC gates were ultrapure, given the stringent gating approach. 8, 14 Differential gene expression analysis and RPKM value estimation was performed using the R/Bioconductor package edgeR, 23 using the raw counts obtained in the previous step as input. Sequencing data were deposited in the Gene Expression Omnibus at GSE111842.
To estimate the relative purity of our samples, we performed a cell enrichment analysis using the online tool xCell, which compares the gene expression profile of each sample with the gene expression signature of 64 immune and stroma cell types. 24 The xCell heatmap was created using GraphPad Prism. 24 For Ingenuity Pathway Analysis (IPA; Qiagen), the differential gene expression lists comparing samples either based on sample type (CTCs, PTs, and PB) or clinical parameters (triple-negative breast cancer, ER-positive, human epidermal growth factor receptor 2 [HER2]-positive, pathologic complete response [pCR]) were used and a core analysis was run using default settings. For the Kyoto Encyclopedia of Genes and Genomes (KEGG) breast cancer pathway overlay with the differential gene expression data from our data analysis, the KEGG breast cancer curated gene set (n = 151) was used to create a new pathway in the IPA. 25 For survival analysis, the top 75 upregulated genes, after differential gene expression analysis comparing sample groups, were used in cBioPortal to create survival tables using The Cancer Genome Atlas (TCGA; n = 817) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n = 2509) breast cancer data sets. 26, 27 Kaplan-Meier curves were plotted using GraphPad Prism (La Jolla, CA, USA).
RESULTS
Enumeration of CTCs and Clinical Factors
Thirty-three newly diagnosed stage II-III breast cancer patients were accrued, along with 23 healthy female controls used to establish the thresholds for negative gating by FACS. Twenty-nine of 33 patients (88%) were positive for CTCs (at least one CTC per 20 mL) using our rapid processing strategy. The median number of CTCs present in this cohort was seven cells (range 0-65). Clinicopathologic and treatment factors are shown in electronic supplementary Table 2 . Sixteen of 33 patients (48%) received neoadjuvant chemotherapy. We examined the association of tumor size, nodal status, estrogen receptor (ER), progesterone receptor (PR) and HER2 status, as well as the presence/absence of pCR with CTC status. None of these factors were associated with the detection of CTCs (electronic supplementary Table 3 ), which is driven by the fact that 88% of patients were CTC-positive in our assay.
Whole Transcriptome RNA-Seq Gene Expression Profiling
We selected 21 CTC samples to evaluate the feasibility of RNA-seq; 76.1% (16/21) passed quality-control metrics ([ 300,000 uniquely mapping reads). CTC samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors) [p = 0.002]. We collected FFPE PT specimens from 75% (12/16) of these cases; six PB samples were also sequenced as a negative control. Figure 1a shows a principle component analysis demonstrating that, at the whole transcriptome level, the majority of CTC specimens separate to form a cohesive group that is distinct from PB or PTs without any background subtraction. Figure 1b presents a transcriptome heatmap of unsupervised hierarchical clustering (top 10,000 most variable genes) of the CTCs, PB, and PTs, based on normalized read counts, which shows that each specimen type forms a distinct group. Figure 1d is a volcano plot showing the log 2 fold change in expression for every gene in the CTC versus PT comparison on the x-axis, versus statistical significance (-log 10 of the FDR-corrected p-value) on the y-axis (the top five most significantly upregulated genes in CTCs versus PTs were HBB, HAND2, OR52H1, CATSPER4, and CLRN1). Table 1 shows the intrinsic molecular subtyping of CTCs and PTs based on NanoString PAM50 assays, RNAseq results for the PAM50 genes, and the molecular subtype predicted by ER/PR/HER2 testing. Eighty-five percent (11/13) of evaluable specimens showed concordance between the subtype predicted by ER/PR/HER2 testing and NanoString PAM50 of PTs. For all other comparisons, concordance was poor (7.1-28%). Two patients died of metastatic disease, both of whom had high risk of recurrence (ROR) scores based on the PT and high CTC counts. Figure 2 presents selected genes of relevance to breast cancer, many of which are potentially clinically actionable, including ER, PR, HER2, androgen receptor (AR), Ki67, EGFR/RAF/MEK, JAK, IGF-1/PI3 K/AKT/mTOR, cancer stem cell, epithelial, mesenchymal, proliferation, immune, and DNA mismatch repair genes. Marked heterogeneity in gene expression was observed across all samples. Strikingly, no single marker was universally present in all CTCs, and there was significant overlap in expression of biomarkers with both PTs and PB for many genes. Figure 3a shows the marked heterogeneity of CTCs for PAM50 genes, as shown in a heatmap comparing CTCs MDM4  RB1  ATM  BRAF  KRAS  NF1  MDM2  TP53  PIK3R1  CCND2  MYC  KI67  CENPF  NOTCH1  JAK2  MAP2K1  ID2  CCND3  CDC25B  TGFB1  MAP3K1  FBXW7  CD44  CXCR4  VIM  TRAC  KRT19  SLUG/SNAI2  FN1  CCND1  CDKN2A  CXCL9  KRT5  CD24  GATA3  HER2  EpCAM  CDKN2B  KRT18  CCNB1  RPTOR  NES  FGFR2  ESR1  CDH1/E cadherin  CXXC5  KIT  BRCA2  CCNA2  BIRC5  CDK6  CCNB2  CD133/PROM1  SFRP1  IL6  EGFR  MYBL2  CDC25A  IGF 1  IL12A  KRT4  TWIST1  PGR  WNT1  CENPA  IL4  PALB2  PTTG1  AURKB  IL23A  CCNE1  CDH2  AKT3  POU5F1  NOTCH4  CCNA1  PIK3CA  PDL1  AKT1  ALDH1A2  BARD1  TBX3  SNAIL  CDK4  IL15  CDC25C  FGF1  CDK1  PLK1  CXCL13  ALDH1A1  SOX2  ID1  TBXA2R  ABCG2  BRCA1  GRB7  AR  KRT8  MET  NANOG  ESR2  CD3D  TRBC1 log(RPKM+1) Figure 4 presents Kaplan-Meier curves comparing the gene signature of PTs versus PB, CTCs versus PB, and using TCGA and METABRIC cohorts 28, 29 . In both cohorts, the gene signature of the shared top 75 upregulated genes in common between CTCs and PTs versus PB was prognostic of worse overall survival, while the signature found in CTCs alone versus PB was not prognostic.
Molecular Subtyping of CTCs
Genes of Relevance to Breast Cancer and Signaling Pathways
Validation with Publically Available Datasets
Analysis of Cellular Composition
Electronic supplementary Fig. 2 presents the results for an analysis of the cellular heterogeneity based on the whole transcriptome profiles of each specimen type. 24 Based on enrichment analysis for 64 known immune and stromal cell types, CTC lysates have a distinct cellular composition that appears to be intermediate between PTs and PB for epithelial versus immune markers. Electronic supplementary Fig. 3 shows the results of NanoString assays of FFPE tumors for clinical-grade biomarkers.
DISCUSSION
In this pilot study, we found that the PB of nearly 90% of stage II-III breast cancer patients harbors CTCs when CTCs are freshly isolated immediately after blood draw. RNA-seq profiling of CTCs allows for a liquid biopsy characterizing potential precursors of metastatic disease at the whole transcriptome level, with comparison to matched PTs. This study is one of the first to perform whole transcriptome profiling of CTCs in non-metastatic breast cancer patients, although others have evaluated multigene panels. 30 We showed that RNA-seq of CTCs is feasible and that such profiling could be used to better understand what tumor characteristics in CTCs may allow for metastasis so that CTCs could be treated with molecularly-directed therapies.
Based on the extremely heterogeneous tumor biology of CTCs, it seems unlikely that single marker-based assays or limited panel multimarker assays could adequately characterize the tumor biology of CTCs to identify opportunities for targeted therapies, and that entire pathways should be examined instead, until suitable targets are known a priori. This information could complement DNA sequencing to predict therapeutic targets. 31 We have also recently published findings showing that multiple target enrichment in NanoString PAM50 resulted in false positive detection of gene transcripts in spiked CTC mimics, and noted potential confounding issues related to the overlap of genes of interest for signal in enriched CTCs and PB. 32 Our xCell analysis indicated that all sample types profiled contained mixed populations of tumor and immune cells as its default is to show a heterogeneous population. Any nucleated cells that are EpCAM high, CD45 low are isolated with our gating strategy, but we have previously shown that this method achieves highly enriched CTCs and that healthy controls do not have CTCs detected via IE/ FACS. 8, 14 xCell phenotyping indicated that CTC lysates contained erythrocytes, and, indeed, we found high expression of b-globin (HBB) in CTCs relative to PTs. Zheng et al. previously reported high HBB expression in CTCs; HBB expression was shown to decrease reactive oxygen species in CTCs, protecting them from apoptosis. The xCell analysis suggested that CTCs express immune markers, perhaps as a strategy to evade immune surveillance. The limitation of perhaps an insufficient number of replicates for centroid-based intrinsic subtype classification for CTCs, with their inherently lower sequencing coverage, led us to conclude that we should focus our attention on highly expressed genes in CTCs, differentially expressed genes in CTCs versus PTs and CTCs versus PB, as well as pathway analysis, to better understand the tumor biology of CTCs.
CTCs highly expressed HAND2, which is reported to decrease ESR1 transcriptional activity. 33 CTCs also strongly expressed WNT8A, 34 PIK3CB, 35 and ESR2, 36 in addition to the OR52H1, CATSPER4, and CLRN1 genes, which were not previously associated with breast cancer. EGFR was expressed in half of the CTCs (Fig. 2) and AR was expressed in 37.5% of CTCs, while PDL1 was not expressed in any of the CTCs, in contrast to a previously published report. 37 We interpret the fact that a 75-gene signature of the most upregulated genes in common between CTCs and PTs was prognostic for survival in two independent datasets, such that CTCs as a liquid biopsy may add value to determining prognosis based on PT features.
CONCLUSIONS
It is feasible to use RNA-seq of CTCs in non-metastatic breast cancer patients as a liquid biopsy of the status of tumor biology, as has been previously demonstrated in metastatic malignancies. 38, 39 This approach is hypothesisgenerating for potentially targeting tumor biology based on CTCs to eradicate the minimal residual disease responsible for subsequent recurrence.
